T2 Biosystms Stock Fundamentals
| TTOO Stock | USD 0.57 0.07 14.00% |
T2 Biosystms fundamentals help investors to digest information that contributes to T2 Biosystms' financial success or failures. It also enables traders to predict the movement of TTOO Stock. The fundamental analysis module provides a way to measure T2 Biosystms' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to T2 Biosystms stock.
At this time, T2 Biosystms' Depreciation And Amortization is very stable compared to the past year. As of the 1st of December 2024, Total Revenue is likely to grow to about 9.8 M, while Interest Expense is likely to drop about 4.9 M. TTOO | Select Account or Indicator |
T2 Biosystms Company Return On Equity Analysis
T2 Biosystms' Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current T2 Biosystms Return On Equity | -6.22 |
Most of T2 Biosystms' fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, T2 Biosystms is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
TTOO Total Stockholder Equity
Total Stockholder Equity |
|
Based on the latest financial disclosure, T2 Biosystms has a Return On Equity of -6.2214. This is 74.05% lower than that of the Biotechnology sector and 6.87% lower than that of the Health Care industry. The return on equity for all United States stocks is notably higher than that of the company.
T2 Biosystms Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining T2 Biosystms's current stock value. Our valuation model uses many indicators to compare T2 Biosystms value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across T2 Biosystms competition to find correlations between indicators driving T2 Biosystms's intrinsic value. More Info.T2 Biosystms is rated below average in return on equity category among its peers. It also is rated below average in return on asset category among its peers . At this time, T2 Biosystms' Return On Equity is very stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the T2 Biosystms' earnings, one of the primary drivers of an investment's value.TTOO Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses T2 Biosystms' direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of T2 Biosystms could also be used in its relative valuation, which is a method of valuing T2 Biosystms by comparing valuation metrics of similar companies.T2 Biosystms is currently under evaluation in return on equity category among its peers.
TTOO Fundamentals
| Return On Equity | -6.22 | ||||
| Return On Asset | -0.9 | ||||
| Operating Margin | (4.91) % | ||||
| Current Valuation | 28.9 M | ||||
| Shares Outstanding | 21.04 M | ||||
| Shares Owned By Insiders | 10.17 % | ||||
| Shares Owned By Institutions | 73.51 % | ||||
| Number Of Shares Shorted | 1.02 M | ||||
| Price To Earning | (2.04) X | ||||
| Price To Book | 14.50 X | ||||
| Price To Sales | 1.68 X | ||||
| Revenue | 7.19 M | ||||
| Gross Profit | (24.77 M) | ||||
| EBITDA | (43.88 M) | ||||
| Net Income | (50.08 M) | ||||
| Cash And Equivalents | 13.21 M | ||||
| Cash Per Share | 1.87 X | ||||
| Total Debt | 49.5 M | ||||
| Debt To Equity | 6.64 % | ||||
| Current Ratio | 1.87 X | ||||
| Book Value Per Share | (6.91) X | ||||
| Cash Flow From Operations | (48.14 M) | ||||
| Short Ratio | 1.26 X | ||||
| Earnings Per Share | (0.03) X | ||||
| Target Price | 5.0 | ||||
| Number Of Employees | 113 | ||||
| Beta | 0.38 | ||||
| Market Capitalization | 10.48 M | ||||
| Total Asset | 34.8 M | ||||
| Retained Earnings | (584.3 M) | ||||
| Working Capital | (30.96 M) | ||||
| Current Asset | 77.78 M | ||||
| Current Liabilities | 18.54 M | ||||
| Net Asset | 34.8 M |
About T2 Biosystms Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze T2 Biosystms's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of T2 Biosystms using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of T2 Biosystms based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 224 K | 212.8 K | |
| Total Revenue | 7.2 M | 9.8 M | |
| Cost Of Revenue | 15.4 M | 17.9 M | |
| Stock Based Compensation To Revenue | 0.60 | 0.57 | |
| Sales General And Administrative To Revenue | 1.58 | 1.50 | |
| Research And Ddevelopement To Revenue | 1.97 | 1.87 | |
| Capex To Revenue | 0.03 | 0.03 | |
| Revenue Per Share | 2.76 | 2.62 | |
| Ebit Per Revenue | (6.90) | (7.25) |
Check out T2 Biosystms Piotroski F Score and T2 Biosystms Altman Z Score analysis. To learn how to invest in TTOO Stock, please use our How to Invest in T2 Biosystms guide.You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of T2 Biosystms. If investors know TTOO will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about T2 Biosystms listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.03) | Revenue Per Share 0.999 | Quarterly Revenue Growth (0.01) | Return On Assets (0.90) | Return On Equity (6.22) |
The market value of T2 Biosystms is measured differently than its book value, which is the value of TTOO that is recorded on the company's balance sheet. Investors also form their own opinion of T2 Biosystms' value that differs from its market value or its book value, called intrinsic value, which is T2 Biosystms' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because T2 Biosystms' market value can be influenced by many factors that don't directly affect T2 Biosystms' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between T2 Biosystms' value and its price as these two are different measures arrived at by different means. Investors typically determine if T2 Biosystms is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, T2 Biosystms' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.